Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD for VR-induced psychosocial stress, anxiety, and nausea in healthy adults
ACTRN12623000872639Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anxiety disorder, motion sickness and Cybersickness comparing Cannabidiol with Placebo (2 arms). Primary endpoints: Change in subjective stress rating on 100 mm Visual Analog Scale and Change in subjective nausea rating on 100 mm Visual Analog Scale. Started Oct 2023; status: completed.
02
Drugs
cannabidiol
03
Conditions
anxiety disordermotion sicknessCybersickness
Beyond the preview
Go deeper on ACTRN12623000872639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000872639.